[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100625793":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":31,"centralContacts":35,"locations":25,"responsibleParty":45,"collaborators":25,"id":47,"slug":48,"hasResults":49,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":25,"eligibilityCriteria":53,"healthyVolunteers":49,"sex":54,"minAge":55,"maxAge":25,"enrollmentInfo":56,"targetDuration":25,"studyType":59,"phases":60,"briefSummary":62,"conditions":63,"keywords":25,"overallStatus":65,"whyStopped":25,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":25},{"fullName":5,"class":6},"Steno Diabetes Center Copenhagen","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Visit GCN","ACTIVE_COMPARATOR","Plasma and sensor glucose are monitored before, during, and after a bout of moderate-intensity exercise shortly after consumption of a meal. Before exercise initiation, participants will be given low-dose glucagon to prevent hypoglycemia.",[13],"Drug: Low-Dose Glucagon",{"label":15,"type":10,"description":16,"interventionNames":17},"Visit CHO","Plasma and sensor glucose are monitored before, during, and after a bout of moderate-intensity exercise shortly after consumption of a meal. Before exercise initiation, participants will be given a dose of glucose to prevent hypoglycemia.",[18],"Dietary Supplement: Glucose Arm",[20,26],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Low-Dose Glucagon","Participants will be given a low-dose of glucagon before starting the exercise session",[9],null,{"type":27,"name":28,"description":29,"armGroupLabels":30,"otherNames":25},"DIETARY_SUPPLEMENT","Glucose Arm","Participants will be given a dose of glucose before starting exercise",[15],[32],{"name":33,"affiliation":5,"role":34},"Kirsten Nørgaard, MD, Professor","STUDY_DIRECTOR",[36,41],{"name":37,"role":38,"phone":39,"phoneExt":25,"email":40},"Emilie Lindkvist, MD, PhD Candidate","CONTACT","+45 21563054","emilie.lindkvist@regionh.dk",{"name":42,"role":38,"phone":43,"phoneExt":25,"email":44},"Sissel Lundemose, MD, PhD","+4523742764","sissel.lundemose@regionh.dk",{"type":46,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100625793","phase-4-the-postprandial-hypo-avoid-study-100625793",false,"NCT07427251","The Postprandial Hypo-Avoid Study","Low-Dose Glucagon and Automated Insulin Delivery for Prevention of Spontaneous Exercise-Induced Hypoglycemia in People With Type 1 Diabetes","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Type 1 diabetes ≥ 2 years\n* Using an automated insulin delivery system for ≥ 3 months\n* NovoRapid or Fiasp use ≥1 week\n* Proficiency in carbohydrate counting\n\nExclusion Criteria:\n\n* Allergies to lactose or glucagon\n* Known or suspected allergies to glucagon or related products\n* History of hypersensitivity or allergic reaction to glucagon or lactose\n* Patients with diagnosed pheochromocytoma, insulinoma or gastroparesis\n* Concomitant medical or psychological conditions identified through review of medical history, physical examination and clinical laboratory analysis that, according to the investigator's assessment, makes the individual unsuitable for study participation\n* Lack of compliance with key study procedures at the discretion of the investigator\n* Females of childbearing potential who are pregnant, breast-feeding or intend to become pregnant or are not using adequate contraceptive methods (methods are considered adequate for study enrolment for females: an intrauterine device, hormonal contraception (birth control pills, implant, patch, vaginal ring or injection), a single partner who is sterile or infertile, or sexual abstinence. Contraception is required throughout the study duration. Sterilized or postmenopausal women (\\>12 months since last period) are not required to use contraception)\n* Inability to understand the individual information and to give informed consent","ALL","18 Years",{"count":57,"type":58},18,"ESTIMATED","INTERVENTIONAL",[61],"PHASE4","The objective of the study is to evaluate whether pre-exercise administration of low-dose subcutaneous glucagon prevents or attenuates exercise-induced declines in plasma glucose concentration during and after moderate-intensity continuous exercise (MICE) performed approximately 90 minutes after a meal in adults with type 1 diabetes using an automated insulin delivery (AID) system.\n\nThe primary endpoint is the difference in the change in plasma glucose (PG) from exercise initiation to the nadir during exercise and through the 2-hour post-exercise period between the glucagon (GCN) and carbohydrate (CHO) visits.",[64],"Type 1 Diabetes Mellitus","NOT_YET_RECRUITING","2026-02-24",{"date":68,"type":69},"2026-02-27","ACTUAL",{"date":71,"type":58},"2026-03-15",{"date":73,"type":58},"2028-05-01",{"name":5,"class":6}]